Ascorbic acid and trolox cell pretreatment decreases carcinogenic Cr(VI)-induced toxicity: A comparative study

Borut Poljšak, M. Pesti, Zoltán Gazdag, J. Belágyi, Peter Raspor

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The biological effects associated with Cr exposure are diverse and depend upon metal speciation. The ability of Cr(VI) to oxidize biomolecules with the formation of Cr(III) complexes is believed to be responsible for the mutagenicity and carcenogenicity of Cr(VI). However, neither Cr(VI) nor Cr(III) alone cause significant DNA damage, which is a necessary but not a sufficient first step en route to cancer. Reactive Cr(V) and Cr(IV) intermediates and reactive oxygen species, formed during the course of Cr(VI) reactions with inracelular reductants, may be the DNA-damaging species. The elucidation of these mechanisms and species responsible for the formation of oxidative DNA lesions upon Cr(VI) treatment is of continuing interest. Since endogenous antioxidant defense systems cannot be activated prior to Cr(VI)-induced oxidative stress, pretreatment with exogenous antioxidants such as ascorbic acid (vitamin C) and Trolox (a water soluble analogue of vitamin E) against Cr(VI)-induced damage was investigated using yeast Saccharomyces cerevisiae as a model organism. The antioxidative potential of ascorbic acid and Trolox was compared under the same experimental conditions in vivo. The objective of this study was to pretreat yeast cells with the same concentration of ascorbic acid and Trolox in order to increase cell tolerance against reactive chromium intermediates and reactive oxygen species formed during chromium(VI) reduction and compare ascorbic acid and Trolox antioxidative protection. Results indicate the important role of increased cytosol reduction capacity on the modification of Cr(V) formation, increased chromium accumulation, and increased scavenging ability of superoxide anions and hydrogen peroxide. Ascorbic acid and Trolox affects Cr(VI) by decreasing Cr(V) persistence, decreasing the levels of intracellular superoxide anions and peroxide formation, and quenching free radicals formed during Cr(VI) to Cr(III) reduction. Many similarities were observed between acorbic acid and Trolox antioxidative protection against Cr(VI)-induced toxicity. Use of yeast S. cerevisiae as a model organism can improve our understanding of the mechanisms by which higher eukaryotes cope with Cr(VI) toxicity.

Original languageEnglish
Title of host publicationCancer Prevention Research Perspectives
PublisherNova Science Publishers, Inc.
Pages1-20
Number of pages20
ISBN (Print)9781612093802
Publication statusPublished - Apr 2011

Fingerprint

Ascorbic Acid
Toxicity
Yeast
Yeasts
Chromium
Superoxides
Saccharomyces cerevisiae
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid
chromium hexavalent ion
Reactive Oxygen Species
DNA
Antioxidants
Oxidative stress
Reducing Agents
Scavenging
Peroxides
Biomolecules
Eukaryota
Vitamin E
Cytosol

Keywords

  • Ascorbic acid
  • Cr(VI)
  • Reactive oxygen species
  • Trolox
  • Yeast

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Poljšak, B., Pesti, M., Gazdag, Z., Belágyi, J., & Raspor, P. (2011). Ascorbic acid and trolox cell pretreatment decreases carcinogenic Cr(VI)-induced toxicity: A comparative study. In Cancer Prevention Research Perspectives (pp. 1-20). Nova Science Publishers, Inc..

Ascorbic acid and trolox cell pretreatment decreases carcinogenic Cr(VI)-induced toxicity : A comparative study. / Poljšak, Borut; Pesti, M.; Gazdag, Zoltán; Belágyi, J.; Raspor, Peter.

Cancer Prevention Research Perspectives. Nova Science Publishers, Inc., 2011. p. 1-20.

Research output: Chapter in Book/Report/Conference proceedingChapter

Poljšak, B, Pesti, M, Gazdag, Z, Belágyi, J & Raspor, P 2011, Ascorbic acid and trolox cell pretreatment decreases carcinogenic Cr(VI)-induced toxicity: A comparative study. in Cancer Prevention Research Perspectives. Nova Science Publishers, Inc., pp. 1-20.
Poljšak B, Pesti M, Gazdag Z, Belágyi J, Raspor P. Ascorbic acid and trolox cell pretreatment decreases carcinogenic Cr(VI)-induced toxicity: A comparative study. In Cancer Prevention Research Perspectives. Nova Science Publishers, Inc. 2011. p. 1-20
Poljšak, Borut ; Pesti, M. ; Gazdag, Zoltán ; Belágyi, J. ; Raspor, Peter. / Ascorbic acid and trolox cell pretreatment decreases carcinogenic Cr(VI)-induced toxicity : A comparative study. Cancer Prevention Research Perspectives. Nova Science Publishers, Inc., 2011. pp. 1-20
@inbook{58191ba1f6fc4d08bd2ff11af37d14a1,
title = "Ascorbic acid and trolox cell pretreatment decreases carcinogenic Cr(VI)-induced toxicity: A comparative study",
abstract = "The biological effects associated with Cr exposure are diverse and depend upon metal speciation. The ability of Cr(VI) to oxidize biomolecules with the formation of Cr(III) complexes is believed to be responsible for the mutagenicity and carcenogenicity of Cr(VI). However, neither Cr(VI) nor Cr(III) alone cause significant DNA damage, which is a necessary but not a sufficient first step en route to cancer. Reactive Cr(V) and Cr(IV) intermediates and reactive oxygen species, formed during the course of Cr(VI) reactions with inracelular reductants, may be the DNA-damaging species. The elucidation of these mechanisms and species responsible for the formation of oxidative DNA lesions upon Cr(VI) treatment is of continuing interest. Since endogenous antioxidant defense systems cannot be activated prior to Cr(VI)-induced oxidative stress, pretreatment with exogenous antioxidants such as ascorbic acid (vitamin C) and Trolox (a water soluble analogue of vitamin E) against Cr(VI)-induced damage was investigated using yeast Saccharomyces cerevisiae as a model organism. The antioxidative potential of ascorbic acid and Trolox was compared under the same experimental conditions in vivo. The objective of this study was to pretreat yeast cells with the same concentration of ascorbic acid and Trolox in order to increase cell tolerance against reactive chromium intermediates and reactive oxygen species formed during chromium(VI) reduction and compare ascorbic acid and Trolox antioxidative protection. Results indicate the important role of increased cytosol reduction capacity on the modification of Cr(V) formation, increased chromium accumulation, and increased scavenging ability of superoxide anions and hydrogen peroxide. Ascorbic acid and Trolox affects Cr(VI) by decreasing Cr(V) persistence, decreasing the levels of intracellular superoxide anions and peroxide formation, and quenching free radicals formed during Cr(VI) to Cr(III) reduction. Many similarities were observed between acorbic acid and Trolox antioxidative protection against Cr(VI)-induced toxicity. Use of yeast S. cerevisiae as a model organism can improve our understanding of the mechanisms by which higher eukaryotes cope with Cr(VI) toxicity.",
keywords = "Ascorbic acid, Cr(VI), Reactive oxygen species, Trolox, Yeast",
author = "Borut Poljšak and M. Pesti and Zolt{\'a}n Gazdag and J. Bel{\'a}gyi and Peter Raspor",
year = "2011",
month = "4",
language = "English",
isbn = "9781612093802",
pages = "1--20",
booktitle = "Cancer Prevention Research Perspectives",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Ascorbic acid and trolox cell pretreatment decreases carcinogenic Cr(VI)-induced toxicity

T2 - A comparative study

AU - Poljšak, Borut

AU - Pesti, M.

AU - Gazdag, Zoltán

AU - Belágyi, J.

AU - Raspor, Peter

PY - 2011/4

Y1 - 2011/4

N2 - The biological effects associated with Cr exposure are diverse and depend upon metal speciation. The ability of Cr(VI) to oxidize biomolecules with the formation of Cr(III) complexes is believed to be responsible for the mutagenicity and carcenogenicity of Cr(VI). However, neither Cr(VI) nor Cr(III) alone cause significant DNA damage, which is a necessary but not a sufficient first step en route to cancer. Reactive Cr(V) and Cr(IV) intermediates and reactive oxygen species, formed during the course of Cr(VI) reactions with inracelular reductants, may be the DNA-damaging species. The elucidation of these mechanisms and species responsible for the formation of oxidative DNA lesions upon Cr(VI) treatment is of continuing interest. Since endogenous antioxidant defense systems cannot be activated prior to Cr(VI)-induced oxidative stress, pretreatment with exogenous antioxidants such as ascorbic acid (vitamin C) and Trolox (a water soluble analogue of vitamin E) against Cr(VI)-induced damage was investigated using yeast Saccharomyces cerevisiae as a model organism. The antioxidative potential of ascorbic acid and Trolox was compared under the same experimental conditions in vivo. The objective of this study was to pretreat yeast cells with the same concentration of ascorbic acid and Trolox in order to increase cell tolerance against reactive chromium intermediates and reactive oxygen species formed during chromium(VI) reduction and compare ascorbic acid and Trolox antioxidative protection. Results indicate the important role of increased cytosol reduction capacity on the modification of Cr(V) formation, increased chromium accumulation, and increased scavenging ability of superoxide anions and hydrogen peroxide. Ascorbic acid and Trolox affects Cr(VI) by decreasing Cr(V) persistence, decreasing the levels of intracellular superoxide anions and peroxide formation, and quenching free radicals formed during Cr(VI) to Cr(III) reduction. Many similarities were observed between acorbic acid and Trolox antioxidative protection against Cr(VI)-induced toxicity. Use of yeast S. cerevisiae as a model organism can improve our understanding of the mechanisms by which higher eukaryotes cope with Cr(VI) toxicity.

AB - The biological effects associated with Cr exposure are diverse and depend upon metal speciation. The ability of Cr(VI) to oxidize biomolecules with the formation of Cr(III) complexes is believed to be responsible for the mutagenicity and carcenogenicity of Cr(VI). However, neither Cr(VI) nor Cr(III) alone cause significant DNA damage, which is a necessary but not a sufficient first step en route to cancer. Reactive Cr(V) and Cr(IV) intermediates and reactive oxygen species, formed during the course of Cr(VI) reactions with inracelular reductants, may be the DNA-damaging species. The elucidation of these mechanisms and species responsible for the formation of oxidative DNA lesions upon Cr(VI) treatment is of continuing interest. Since endogenous antioxidant defense systems cannot be activated prior to Cr(VI)-induced oxidative stress, pretreatment with exogenous antioxidants such as ascorbic acid (vitamin C) and Trolox (a water soluble analogue of vitamin E) against Cr(VI)-induced damage was investigated using yeast Saccharomyces cerevisiae as a model organism. The antioxidative potential of ascorbic acid and Trolox was compared under the same experimental conditions in vivo. The objective of this study was to pretreat yeast cells with the same concentration of ascorbic acid and Trolox in order to increase cell tolerance against reactive chromium intermediates and reactive oxygen species formed during chromium(VI) reduction and compare ascorbic acid and Trolox antioxidative protection. Results indicate the important role of increased cytosol reduction capacity on the modification of Cr(V) formation, increased chromium accumulation, and increased scavenging ability of superoxide anions and hydrogen peroxide. Ascorbic acid and Trolox affects Cr(VI) by decreasing Cr(V) persistence, decreasing the levels of intracellular superoxide anions and peroxide formation, and quenching free radicals formed during Cr(VI) to Cr(III) reduction. Many similarities were observed between acorbic acid and Trolox antioxidative protection against Cr(VI)-induced toxicity. Use of yeast S. cerevisiae as a model organism can improve our understanding of the mechanisms by which higher eukaryotes cope with Cr(VI) toxicity.

KW - Ascorbic acid

KW - Cr(VI)

KW - Reactive oxygen species

KW - Trolox

KW - Yeast

UR - http://www.scopus.com/inward/record.url?scp=84892035453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892035453&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84892035453

SN - 9781612093802

SP - 1

EP - 20

BT - Cancer Prevention Research Perspectives

PB - Nova Science Publishers, Inc.

ER -